Et studie om samtidig administration af CellCept (1 g 2 gange daglig) og orale kontraceptiva af kombinationstypen indeholdende ethinylestradiol (0, 02- 0, 04 mg) og levonorgestrel (0, 05- 0, 15 mg), desogestrel (0, 15 mg) eller gestoden (0, 05 – 0, 10 mg) hos 18 ikke- transplanterede kvinder (som ikke fik andre immunosuppressiva) i 3 konsekutive menstruationscykler viste ingen klinisk relevant påvirkning af CellCept på den ovulationshæmmende virkning af de orale kontraceptiva.
A study of the coadministration of CellCept (1 g bid) and combined oral contraceptives containing ethinylestradiol (0.02 mg to 0.04 mg) and levonorgestrel (0.05 mg to 0.15 mg), desogestrel (0.15 mg) or gestodene (0.05 mg to 0.10 mg) conducted in 18 non-transplant women (not taking other immunosupressants) over 3 consecutive menstrual cycles showed no clinically relevant influence of CellCept on the ovulation suppressing action of the oral contraceptives.